• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection and immunity >Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug
【24h】

Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug

机译：通过结合基于质粒DNA的免疫与席夫碱形成药物显着增强抗原特异性免疫反应。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although plasmid DNA (pDNA)-based immunization has proven efficacy, the level of immune responses that is achieved by this route of vaccination is often lower than that induced by traditional vaccines, especially for primates and humans. We report here a simple and potent method to enhance pDNA-based vaccination by using two different plasmids encoding viral or bacterial antigens. This method is based on coadministration of low concentrations of a recently described immunopotentiating, Schiff base-forming drug called tucaresol which has led to significant augmentation of antigen-specific humoral and cellular immune responses. Our data suggest that enhancement of the immune response with tucaresol might provide a powerful tool for the further development of pDNA-based immunization for humans.
机译：尽管基于质粒DNA（pDNA）的免疫已被证明是有效的，但是通过这种疫苗接种途径实现的免疫应答水平通常低于传统疫苗诱导的水平，尤其是对于灵长类动物和人类。我们在这里报告了一种简单有效的方法，可通过使用两种编码病毒或细菌抗原的不同质粒来增强基于pDNA的疫苗接种。该方法基于低剂量的最近描述的免疫增强，席夫碱形成药物称为托卡雷索的共同给药，该药物已导致抗原特异性体液和细胞免疫应答的显着增强。我们的数据表明，用托卡雷索增强免疫反应可能为进一步开发基于pDNA的人类免疫提供强大的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号